| First Author | Zhao S | Year | 2020 |
| Journal | Int J Mol Sci | Volume | 21 |
| Issue | 4 | PubMed ID | 32075272 |
| Mgi Jnum | J:297870 | Mgi Id | MGI:6479353 |
| Doi | 10.3390/ijms21041315 | Citation | Zhao S, et al. (2020) IL-27Ralpha: A Novel Molecular Imaging Marker for Allograft Rejection. Int J Mol Sci 21(4):1315 |
| abstractText | Non-invasively monitoring allogeneic graft rejection with a specific marker is of great importance for prognosis of patients. Recently, data revealed that IL-27Ralpha was up-regulated in alloreactive CD4(+) T cells and participated in inflammatory diseases. Here, we evaluated whether IL-27Ralpha could be used in monitoring allogeneic graft rejection both in vitro and in vivo. Allogeneic (C57BL/6 donor to BALB/c recipient) and syngeneic (BALB/c both as donor and recipient) skin grafted mouse models were established. The expression of IL-27Ralpha in grafts was detected. The radio-probe, (125)I-anti-IL-27Ralpha mAb, was prepared. Dynamic whole-body phosphor-autoradiography, ex vivo biodistribution and immunofluorescence staining were performed. The results showed that the highest expression of IL-27Ralpha was detected in allogeneic grafts on day 10 post transplantation (top period of allorejection). (125)I-anti-IL-27Ralpha mAb was successfully prepared with higher specificity and affinity. Whole-body phosphor-autoradiography showed higher radioactivity accumulation in allogeneic grafts than syngeneic grafts on day 10. The uptake of (125)I-anti-IL-27Ralpha mAb in allogeneic grafts could be almost totally blocked by pre-injection with excess unlabeled anti-IL-27Ralpha mAb. Interestingly, we found that (125)I-anti-IL-27Ralpha mAb accumulated in allogeneic grafts, along with weaker inflammation earlier on day 6. The high uptake of (125)I-anti-IL-27Ralpha mAb was correlated with the higher infiltrated IL-27Ralpha positive cells (CD3(+)/CD68(+)) in allogeneic grafts. In conclusion, IL-27Ralpha may be a novel molecular imaging marker to predict allorejection. |
